Gout – Landscape & Forecast – Disease Landscape & Forecast

Gout is a painful, systemic inflammatory condition caused by elevated serum uric acid and characterized by intermittent acute flares. Treatment of acute gout flares typically involves NSAIDs, colchicine, corticosteroids, and anti-IL-1 agents. Long-term urate-lowering drugs (ULDs), such as xanthine oxidase inhibitors (XOIs), uricosuric agents, and uricase analogues, are the cornerstone of chronic gout management. Despite the availability of these treatments, physicians, patients, and healthcare systems have concerns about their limitations. The gout therapy market will expand over the 2022-2032 study period, fueled by an increasing diagnosed gout population and demand for new drugs that can effectively, safely, and conveniently control the disease. Several drugs are in clinical development, including uricase analogues, XOIs, URAT1 inhibitors, and inhibitors of the NOD-like receptor protein-3 (NLRP3) inflammasome.

QUESTIONS ANSWERED

  • What are the incidence and prevalence of gout in the major pharmaceutical markets under study?
  • How is gout currently treated? What are experts’ opinions of Horizon Pharma’s Krystexxa as a treatment for chronic refractory gout?
  • What is the commercial potential of emerging therapies? How do leaders in the field of gout management rate these drug candidates?
  • How will the gout therapy market evolve over the next 10 years?

CONTENT HIGHLIGHTS

  • Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
  • Primary research: 19 country-specific interviews with thought-leading rheumatologists. Supported by survey data collected for this and other Clarivate research.
  • Epidemiology: Incidence and prevalence of diagnosed gout population by country and drug-treated rates.
  • Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
  • Market forecast features: 10-year, annualized, drug-level sales and patient share of key gout therapies through 2032, segmented by brands / generics.

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold. Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Gout - Landscape & Forecast - Disease Landscape & Forecast
    • Key Findings
      • Gout Key Findings - August 2023
    • Key Updates
      • August 2023
    • Market Outlook
      • Key findings
        • Market share of drug classes for acute gout: 2022
        • Market share of drug classes for chronic gout: 2022
        • Market share of drug classes for acute gout: 2032
        • Market share of drug classes for chronic gout: 2032
        • Gout SWOT analysis
      • Market drivers and constraints
        • What factors are driving the market for gout?
        • What factors are constraining the market for gout?
        • Key market events for gout: 2022-2032
        • Total gout sales by populations in the major markets: 2022-2032
        • Total sales by drug class for chronic gout in the major markets: 2022-2032
        • Patient share by drug class for chronic gout in the major markets: 2022-2032
      • Drug-class-specific trends
        • Annual sales of xanthine oxidase inhibitors in the major markets: 2022-2032
        • Patient share of xanthine oxidase inhibitors in the major markets: 2022-2032
        • Annual sales of uricosuric agents in the major markets: 2022-2032
        • Patient share of uricosuric agents in the major markets: 2022-2032
        • Annual sales of uricase analogues in the major markets: 2022-2032
        • Patient share of uricase analogues in the major markets: 2022-2032
        • Total sales by drug class for acute gout in the major markets: 2022-2032
        • Patient share by drug class for acute gout in the major markets: 2022-2032
    • Forecast
      • Market forecast assumptions u2013 acute gout
      • Market forecast assumptions u2013 chronic gout
      • Market forecast dashboard u2013 acute gout
      • Market forecast dashboard u2013 chronic gout
    • Etiology and Pathophysiology
      • Disease overview
      • Etiology
        • Key risk factors contributing to gout
      • Pathophysiology
        • Pathophysiological mechanism of gout
        • Major complications related to gout
      • Disease progression
        • Key pathways and drug targets
          • Drug targets
      • Epidemiology
        • Key findings
          • Epidemiology populations
            • Disease definition, methods, and sources used
            • Diagnosed incident cases of acute gout: 2022-2032
            • Disease definition, methods, and sources used
            • Diagnosed prevalent cases of chronic gout: 2022-2032
            • Drug-treated incident cases of acute gout: 2022-2032
            • Drug-treated prevalent cases of chronic gout: 2022-2032
        • Current Treatment
          • Key findings
            • Treatment goals
              • Key endpoints used in clinical trials for gout
            • Key current therapies
              • Overview
              • Mechanism of action of key current drug classes used for gout
              • Current treatments used for gout
              • Advantages and disadvantages of nonsteroidal anti-inflammatory drugs (NSAIDs)
              • Expert insight: nonsteroidal anti-inflammatory drugs (NSAIDs)
              • Advantages and disadvantages of colchicine
              • Expert insight: colchicine
              • Advantages and disadvantages of corticosteroids
              • Expert insight: corticosteroids
              • Advantages and disadvantages of anti-interleukin-1 agents
              • Expert insight: anti-interleukin-1 agents
              • Advantages and disadvantages of allopurinol
              • Expert insight: allopurinol
              • Advantages and disadvantages of febuxostat
              • Expert insight: febuxostat
              • Advantages and disadvantages of topiroxostat
              • Expert insight: topiroxostat
              • Advantages and disadvantages of probenecid
              • Expert insight: probenecid
              • Advantages and disadvantages of benzbromarone
              • Expert insight: benzbromarone
              • Advantages and disadvantages of dotinurad
              • Expert insight: dotinurad
              • Advantages and disadvantages of pegloticase
              • Expert insight: pegloticase
            • Medical practice
              • Overview
              • Factors influencing drug selection in gout
              • Treatment decision tree for gout: United States
              • Treatment decision tree for gout: Europe
              • Treatment decision tree for gout: Japan
          • Unmet Need Overview
            • Current and future attainment of unmet needs in gout
            • Top unmet needs in gout: current and future attainment
          • Drug pipeline
            • Pipeline
            • Regulatory milestones
            • Indication Comparison
          • Access & Reimbursement Overview
            • Region-specific reimbursement practices
              • Key market access considerations in gout: United States
              • General reimbursement environment: United States
              • Key market access considerations in gout: EU5
              • General reimbursement environment: EU5
              • Key market access considerations in gout: Japan
              • General reimbursement environment: Japan
          • Emerging Therapies
            • Key findings
              • Key emerging therapies
                • Key therapies in development for gout
                • Estimated launch dates of key emerging therapies for the treatment of gout
                • Dapansutrile profile
                • Key ongoing clinical trials of dapansutrile in the treatment of gout
                • Analysis of the clinical development program for dapansutrile
                • Expert insight: dapansutrile
                • Expectations for launch and sales opportunity of dapansutrile in acute gout
                • SEL-212 profile
                • Analysis of the clinical development program for SEL-212
                • Expert insight: SEL-212
                • Tigulixostat profile
                • Analysis of the clinical development program for tigulixostat
                • Key ongoing clinical trials of tigulixostat in the treatment of gout
                • Expert insight: tigulixostat
                • Expectations for launch and sales opportunity of tigulixostat in chronic gout
              • Early-phase pipeline analysis
                • Select compounds in early-phase development for gout
            • Appendix
              • Abbreviations
              • Gout bibliography

          Login to access report